Overview

Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
This study will investigate the effect on ambulatory blood pressure of lumiracoxib 100 mg once daily versus ibuprofen 600 mg three times a day in osteoarthritis patients with controlled hypertension.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Diclofenac
Ibuprofen
Lumiracoxib
Criteria
Inclusion Criteria:

- Osteoarthritis of the hand, hip, knee or spine

- High blood pressure (<140/ 90 mmHg) which is controlled by antihypertensive
medication(s).

Exclusion criteria

• Evidence or history of any cardiac and cerebral thrombotic/ ischemic diseases and/ or
events

Other protocol-defined inclusion/exclusion criteria may apply